Processa Pharmaceuticals (PCSA) Market Capitalization (2014 - 2026)

Processa Pharmaceuticals (PCSA) has reported Market Capitalization for 13 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization rose 68.2% year-over-year to $5.4 million; the trailing twelve-month figure through Jun 2026 stood at $5.4 million (up 68.2% YoY), and the FY2025 full-year result was $3.8 million, up 39.4% from the prior year.
• Market Capitalization fell to $5.4 million in Q2 2026 per PCSA's latest filing, from $6.8 million in the prior quarter.
• Across five years, Market Capitalization topped out at $47.7 million in Q1 2022 and bottomed at $2.7 million in Q4 2024.
• Historically, Market Capitalization has averaged $13.2 million across 5 years, with a median of $6.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Market Capitalization plunged 82.86% in 2023, then surged 126.77% in 2025.
• Over 5 years, Market Capitalization stood at $17.6 million in 2022, then sank by 51.15% to $8.6 million in 2023, then plunged by 68.61% to $2.7 million in 2024, then jumped by 39.4% to $3.8 million in 2025, then soared by 42.24% to $5.4 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $5.4 million, $6.8 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.